Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RTI VanishPoint Syringe Gets "Preferred" Rating in ECRI Safe Needle Study

This article was originally published in The Gray Sheet

Executive Summary

Retractable Technologies, Inc.' s VanishPoint syringe is the only disposable syringe to receive a "preferred" rating in a new ECRI study evaluating the safety, ease-of-use, performance and cost-effectiveness of currently available needlestick protection devices (NPDs).

You may also be interested in...



BD To Achieve Safety Products Sales Target Early Aided By OSHA Revision

The Needlestick Safety and Prevention Act and subsequent revision to the Occupational Safety and Health Administration's bloodborne pathogens standard will help BD Corp. reach the $800 mil. sales mark by the end of 2003, the firm is now projecting, well ahead of its earlier forecast of 2005.

BD To Achieve Safety Products Sales Target Early Aided By OSHA Revision

The Needlestick Safety and Prevention Act and subsequent revision to the Occupational Safety and Health Administration's bloodborne pathogens standard will help BD Corp. reach the $800 mil. sales mark by the end of 2003, the firm is now projecting, well ahead of its earlier forecast of 2005.

OSHA Regs Will Not Keep Unsafe Sharps From Workplace - HRG Petition

FDA should remove from the market all blood collection devices and I.V. catheters for which safer alternatives exist, Public Citizen's Health Research Group is urging in a Nov. 29 petition to Commissioner Jane Henney.

Related Content

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel